Pinotbio, Inc.
June 22, 2026
Theater 2
Type: Company Presentation
Focus Area:
Oncology
Pinotbio, Inc. is a clinical stage biotech company developing novel ADC candidates based upon own proprietary platform technologies. Pinot-ADC, Pinotbio's own platform technologies, consist of a novel, proprietay CPT payload, PBX-7016, a super-hydrophilic tandem cleavage linker, and dual payload ADC technologies. Our platform technologies are being employed in several phase I stage ADCs of our partners - CT-P70, 71 and 73 - which show excellent safety and efficacy profile. Also, using Pinot-ADC platform, Pinotbio is making a potential best-in-class ITGB6 ADC, PBX-004. PBX-004 shows better efficacy profile than competitor's ITGB6 ADC candidates and also shows excellent safety profile (at least 30 mpk, HNSTD in repeat dose Cyno Tox studies). Currently, PBX-004 is in preclinical development with the goal of IND approval in 2027. In addition to PBX-004, Pinotbio is making next generation ITGB6 dual payload ADC using PBX-7016 and Triptolide (RNA-pol II inhibitor) combination.
Company HQ City:
Suwon
Company HQ State:
Kyonggi-do
Company HQ Country:
Korea, Republic of
Year Founded:
2017
Lead Product in Development:
CT-P71 - Nectin-4 ADC (licensed out to Celltrion) targeting UC, TNBC, and NSCLC
CEO
CEO - Doo Young Jung, Ph. D.
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
2
When you expect your next catalyst update?
June, 2027
What is your next catalyst (value inflection) update?
IND approval of PBX-004, our own ADC development candidate with potential Best-in-class possibility
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}